AI dermatology lesion triaging market seen reaching $4.47B by 2030

The market for artificial intelligence-powered dermatology lesion triaging is projected to expand from $1.48 billion in 2026 to $4.47 billion by 2030, according to The Business Research Company. Growth is being fueled by rising skin cancer rates, broader use of digital imaging and teledermatology, and demand for faster, more accurate skin lesion assessment.

Why it matters: - AI-powered dermatology lesion triaging is becoming a tool for earlier identification of potentially harmful skin lesions. - Faster risk screening can help dermatology teams prioritize high-risk cases and reduce diagnostic delays. - The market’s growth signals broader adoption of AI in clinical decision support and preventive dermatology.

What happened: - The Business Research Company released its 2026 market report on artificial intelligence-powered dermatology lesion triaging. - The report estimates the market will rise from $1.12 billion in 2025 to $1.48 billion in 2026. - The report projects the market will reach $4.47 billion by 2030, implying a 31.8% CAGR. - North America held the largest share of the global market in 2025.

The details: - AI-powered dermatology lesion triaging uses algorithms and machine learning models to analyze and prioritize skin lesions by risk level. - The technology combines image recognition, pattern analysis and clinical data to support decision-making. - The 2026 growth estimate reflects rising skin disorder prevalence, greater awareness of early cancer detection, expansion of dermatology diagnostic services, wider use of digital imaging and increased focus on preventive dermatology. - Longer-term growth is tied to broader use of AI-assisted diagnostic tools, remote dermatology consultations, cloud-based clinical decision support systems and workflow automation. - The report also points to trends in enhanced AI skin image analysis, automated lesion risk stratification, teledermatology integration, mobile dermatology apps and early skin cancer detection. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - North America is expected to remain the dominant region because of advanced healthcare infrastructure, strong technology adoption and investment in AI-driven medical solutions. - The report includes market attractiveness scoring, total addressable market analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics and trend analysis.

Between the lines: - Skin cancer incidence is a major demand driver because AI triage can help flag suspicious lesions sooner. - Cancer Australia reported about 8,257 new melanoma skin cancer cases in 2023, accounting for 2.6% of all cancer deaths in the country. - The market outlook suggests healthcare providers are moving toward tools that compress review times while expanding access through remote care. - The report’s regional outlook suggests adoption will spread beyond North America as teledermatology and digital health tools mature.

What's next: - The report expects continued market expansion through 2030 as dermatology practices adopt more automated triage and decision-support tools. - Future growth will likely track wider use of teledermatology platforms, mobile apps and cloud-based clinical systems. - The Business Research Company is also offering a free sample and the full market report online: Download the sample report and Read the full report. - The Business Research Company lists contact information for expert inquiries, including marketing@tbrc.info and regional phone numbers.

The bottom line: - AI dermatology lesion triaging is moving from niche application to mainstream clinical workflow, with rapid growth tied to skin cancer detection, digital health adoption and automation.